Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
74.34
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
Is Gilead Sciences Stock a Buy Now?
December 07, 2021
Gilead Sciences is facing multiple headwinds, but there may be hope for the biotech company.
Via
The Motley Fool
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
December 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome...
Via
Benzinga
Gilead Recalls Two Lots Of Remdesivir Due To Presence Of Glass Particulates
December 06, 2021
Gilead Sciences Inc (NASDAQ: GILD) has issued a nationwide recall of two lots of its COVID-19 treatment drug Remdesivir because of the presence of glass...
Via
Benzinga
Topics
Product Recall
Exposures
COVID-19
Legal
Product Safety
December SPAC Merger Calendar: Upcoming Votes, Stocks To Watch
December 05, 2021
The month of December shows an increasing number of SPAC deal votes. SPAC merger votes can act as a catalyst, as the votes complete the last step in the merger process and change...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
December 06, 2021
Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX:
Via
Benzinga
Got $1,000? Check Out These 3 Top Biotech Stocks
December 03, 2021
Two big biotechs and one smaller one that could be winners over the long term.
Via
The Motley Fool
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
November 29, 2021
Smaller companies are working on next-generation approaches to Covid treatment.
Via
Investor's Business Daily
Why Are NRx Pharma's Shares Soaring Premarket?
November 29, 2021
NRx Pharmaceuticals (NASDAQ: NRXP) has completed an analysis in the subgroup of Zyesami and placebo-treated patients previously treated with Gilead Science Inc's...
Via
Benzinga
3 Dividend Stocks That Are Dirt Cheap Right Now
November 25, 2021
If you want dividend growth, dividend safety, and an undervalued stock, these three fit the bill.
Via
The Motley Fool
A Look Into Gilead Sciences Debt
November 24, 2021
Shares of Gilead Sciences (NASDAQ:GILD) fell by 1.76% in the past three months. Before we understand the importance of debt, let us look at how much debt Gilead Sciences...
Via
Benzinga
Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial
November 24, 2021
Gilead Sciences Inc (NASDAQ: GILD) and Merck & Co Inc (NYSE: MRK) have temporarily paused enrollment in the Phase 2 study evaluating the combination...
Via
Benzinga
Gilead's Trodelvy Approved In Europe For Aggressive Form Of Breast Cancer
November 23, 2021
The European Commission has approved Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan) as monotherapy for triple-negative breast cancer (...
Via
Benzinga
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
November 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In...
Via
Benzinga
Exposures
COVID-19
Product Safety
Next Week Trading Opportunities - GILD, ETSY, FCEL, PLUG, SNOW, AAPL
November 21, 2021
With the assistance of AI we can identify patterns, trends, and buy/sell signals. Here are the prospects in the coming week for these six stocks.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
1 Cancer Stock on Buyout Watch in 2022
November 21, 2021
Cardiff Oncology is a prime takeover target heading into 2022.
Via
The Motley Fool
Exposures
COVID-19
Dividend Initiators: A Fertile Ground For Research
November 19, 2021
Only a company with a certain type of business can afford to grow dividends over a full business cycle.
Via
Talk Markets
Gilead Files US Application For Bulevirtide In Severe Form Of Viral Hepatitis
November 19, 2021
Gilead Sciences Inc (NASDAQ: GILD) has submitted a marketing application to FDA for bulevirtide for injection (2 mg) for chronic hepatitis delta virus (HDV)...
Via
Benzinga
Exposures
Product Safety
Arcus Stock Rockets To Record As Gilead Unexpectedly Opts Into Cancer Drugs
November 18, 2021
Gilead opted into three programs from a small biotech company, sending shares flying.
Via
Investor's Business Daily
Why Are Arcus Biosciences Shares Trading Higher Today?
November 18, 2021
Gilead Sciences Inc (NASDAQ: GILD) has exercised its options to three programs in Arcus Biosciences Inc (NYSE: RCUS) portfolio, including both anti-TIGIT...
Via
Benzinga
Why Arcus Biosciences Stock Is On Fire Today
November 18, 2021
Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs.
Via
The Motley Fool
2 High-Yield Dividend Stocks That Can Safeguard Your Portfolio Against a Market Crash
November 15, 2021
AbbVie and Gilead Sciences are two top high-yield stocks that could save your portfolio in the event of a marketwide downturn.
Via
The Motley Fool
Topics
Economy
Exposures
Interest Rates
On Target: This Company Says It Delivers Drugs Exactly How You Need Them
November 15, 2021
Photo by Anna Shvets from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
November 12, 2021
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products.
Via
Talk Markets
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
November 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &...
Via
Benzinga
Top 5 Stocks To Buy In November 2021
November 09, 2021
High-quality dividend growth stocks are some of the very best stocks in the whole world. They represent equity in world-class businesses that pay reliable, rising dividends.
Via
Talk Markets
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
November 06, 2021
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see...
Via
Talk Markets
Best and Worst Performers Since the COVID Crash Low
November 05, 2021
The major indices have consistently been hitting new record highs over the past few days with the S&P 500 having now more than doubled off the COVID Crash low on March 23, 2020.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Will Pfizer Outgun Merck With Oral COVID-19 Pill?
November 05, 2021
Merck, Inc. (NYSE: MRK) is locking horns with peer Pfizer, Inc. (NYSE: PFE) in what could be termed as the battle supremacy in the COVID-19 treatment market. The stakes are high,...
Via
Benzinga
Exposures
COVID-19
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
November 05, 2021
Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.